Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery

NCT02540876 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Malignant Neoplasm
Solid Neoplasm
Unresectable Malignant Neoplasm

Interventions

DRUG: Ilorasertib
OTHER: Laboratory Biomarker Analysis

Sponsor

University of Chicago

Collaborators

[object Object]